[go: up one dir, main page]

McPherson, 1998 - Google Patents

Localization of neutralizing epitopes in the leukotoxin of Pastuerella haemolytica

McPherson, 1998

View PDF
Document ID
5170572914673560786
Author
McPherson J
Publication year

External Links

Snippet

Pasteurella haemolytica A1 is the organism most often isolated from calves with pneumonic pasteurellosis. The primary virulence factor of P. haemolytica is a secreted cytolytic leukotoxin. The leukotoxin (LKT) is a pore forming toxin whose action is restricted to the …
Continue reading at trace.tennessee.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria

Similar Documents

Publication Publication Date Title
Haesebrouck et al. Actinobacillus pleuropneumoniae infections in pigs: the role of virulence factors in pathogenesis and protection
Vasfi Marandi et al. Role of outer membrane protein H (OmpH)-and OmpA-specific monoclonal antibodies from hybridoma tumors in protection of mice against Pasteurella multocida
Chen et al. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization
USRE45467E1 (en) Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications
Dabo et al. Vaccination with Pasteurella multocida recombinant OmpA induces strong but non-protective and deleterious Th2-type immune response in mice
Inzana Virulence properties of Actinobacillus pleuropneumoniae
EP0618813A1 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
US8324354B2 (en) Environmentally regulated genes of Streptococcus suis
CA2170839A1 (en) Bacterial preparations, method for producing same, and their use as vaccines
US6472183B2 (en) Immunity against Actinobacillus pleuropneumoniae's RTX toxins APX
CA2236700C (en) Immunity against pasteurella haemolytica leukotoxin
Chanter et al. Recombinant hyaluronate associated protein as a protective immunogen against Streptococcus equi andStreptococcus zooepidemicus challenge in mice
McPherson Localization of neutralizing epitopes in the leukotoxin of Pastuerella haemolytica
AU2013200079B2 (en) Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications
Oyant et al. Role of Bordetella bronchiseptica adenylate cyclase in nasal colonization and in development of local and systemic immune responses in piglets
Türkmen Development of an Experimental Recombinant Vaccine Formulation Composed of LktA from Mannheimia Haemolytica A1 And P31 And LppB from Histophilus Somni 8025 Against Hovine Respiratory Disease
Schuijffel A strategic approach for immunity-based selection of cross-protective Ornithobacterium rhinotracheale antigens
Luo Cloning and characterization of the major outer membrane porin gene (ompH) of Pasteurella multocida
Pandher Molecular and immunological analyses of 38 kDA and 45 kDA protein antigens of Pasteurella haemolytica S1
Gerbig Jr Generation of monoclonal antibodies to Pasteurella haemolytica leukotoxin: Characterization of a neutralizing monoclonal antibody
Cullen The Role of Humoral and Cellular Defences of the Pig Against Actinobacillus pleuropneumoniae
Hormozi Activation and immunogenicity of Bordetella pertussis adenylate cyclase toxin
CA2371022A1 (en) Genetically engineered oral commensal organisms as vaccines
HK1120076B (en) Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications